Compare Pfizer Inc (PFE) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Pfizer Inc trades at $28.1 (market cap $158.56B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.5 (market cap $1.45B). The key difference: Pfizer Inc is far larger — about 109.4× Direxion NASDAQ 100 Equal Weighted Index Shares's market cap, and Pfizer Inc pays a 6.18% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Direxion NASDAQ 100 Equal Weighted Index Shares for 47 Days on average.
| PFE | QQQE | |
|---|---|---|
Market Cap | $158.56B | $1.45B |
Volume | 44,138,282 | 323,568 |
Sector | Health | Broad Market / Factor |
52-Week High | $29.02 | $124.69 |
52-Week Low | $23.67 | $96.06 |
Typical Hold Time | 158 Days | 47 Days |
Enterprise Value | $210.06B | — |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
QQQE trades at $121.89, down 0.89% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF provides equal-weighted exposure to NASDAQ-100 large-cap growth stocks, reducing technology concentration compared to market-cap weighted alternatives. Recent analysis highlights QQQE's tactical appeal for diversification within tech-heavy indices.
The equal-weight methodology offers fundamental diversification benefits, though specific financial ratios are unavailable for the ETF structure. Market sentiment appears constructive with technical strength, but investors face typical ETF risks including market volatility and sector concentration despite the equal-weight approach.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
